AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
Pediatric Endocrine Society (PES) Annual Meeting, held May 2-5, 2024, in Chicago, IL
Abstract, OraGrowtH210 Trial (Phase 2): Oral LUM-201 Shows Similar Annualized Height Velocity to Daily rhGH in Moderate Pediatric Growth Hormone Deficiency (PGHD) with a 1.6mg/kg/day Dose and a Promising Investigational Safety Record, Andrew Dauber, MD, et al, to be presented in a poster session, Friday, May 3rd, 12:15-1:45 PM CT
The 10th International Congress of the Growth Hormone Research Society (GRS), held May 10-11, 2024, in Stockholm, Sweden
Abstract, Approaching the reality of restoring GH secretion and growth with the investigative oral growth hormone secretagogue (GHS) LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD), Peter Clayton, MD, PhD, et al, to be presented in an oral session, Friday, May 10th, 12:00-1:00 PM CET
European Congress of Endocrinology (ECE) 2024, held May 11-14, 2024, in Stockholm, Sweden
Abstract, Approaching the reality of restoring GH secretion and growth with the investigative oral growth hormone secretagogue (GHS) LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD), Peter Clayton, MD, PhD, et al, to be presented in an oral session, Sunday, May 12th, 4:20-6:00 PM CET
"We are excited to share additional data analyses from our Phase 2 OraGrowtH Trials with the global endocrine community at these key medical meetings," said Rick Hawkins, Lumos Pharma's Chairman and CEO. "Our Phase 2 data to date have demonstrated that, by augmenting the natural pulsatile secretion of growth hormone, our oral therapeutic candidate, LUM-201, produces comparable growth to injectable rhGH with significantly less exposure to circulating GH. We believe this information will continue to resonate throughout the endocrine community and that oral LUM-201 could create a paradigm shift in the way PGHD and other growth hormone disorders are treated."
About LUM-201
LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland.1 LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release and to suppress the release of somatostatin.2 LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion in humans, which mimics the natural pattern of GH secretion. 3,4 This therapeutic candidate has been studied in more than 1,300 patients, both adult and pediatric, and was generally well tolerated with the most commonly reported adverse events being digestive systems events, including appetite increase. Mild elevations in liver enzymes without accompanying changes in bilirubin were also reported. LUM-201 has received Orphan Drug Designation in both the US and EU.
1 Patchett A.A., et al. Design and Biological Activities of L-163,191 (MK-0677): A Potent, Orally Active Growth Hormone Secretagogue, Proc Natl Acad Sci, 1995, 92:7001-7005.
2 Howard A.D., et al. A Receptor in Pituitary and Hypothalamus that Functions in Growth Hormone Release, Science, 1996, 273:974-977.
3 Nass R., et al. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults, Ann Intern Med, 2008, 149:601-611.
4 Chapman I.M., et al. Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults, J Clin Endocrinol Metab, 1997, 82(10):3455-3463.
得克薩斯州奧斯汀,2024年4月18日(環球新聞專線)——通過2期臨床試驗推進兒科生長激素缺乏症(PGHD)口服療法候選藥物的生物製藥公司Lumos Pharma, Inc.(納斯達克股票代碼:LUMO)今天宣佈,審查其2期OraGrowth210和OraGrowth212試驗數據的摘要將在即將在美國和歐洲舉行的幾次醫學會議上公佈。
兒科內分泌學會 (PES) 年會,2024 年 5 月 2-5 日在伊利諾伊州芝加哥舉行
生長激素研究學會(GRS)第十屆國際大會,於2024年5月10日至11日在瑞典斯德哥爾摩舉行
2024 年歐洲內分泌學大會 (ECE),2024 年 5 月 11 日至 14 日在瑞典斯德哥爾摩舉行
Lumos Pharma董事長兼首席執行官裏克·霍金斯表示:“我們很高興在這些重要的醫學會議上與全球內分泌界分享我們的2期OraGrowth試驗的更多數據分析。”“我們迄今爲止的第二階段數據表明,通過增加生長激素的自然脈動分泌,我們的口服候選藥物 LUM-201 可產生與可注射的生長激素相當的生長,而循環生長激素的暴露量明顯減少。我們相信,這些信息將繼續引起整個內分泌界的共鳴,口服 LUM-201 可能會改變 PGHD 和其他生長激素疾病的治療方式。”
關於 LUM-201
LUM-201(ibutamoren)是一種口服給藥的小分子,可促進垂體生長激素(GH)的分泌(促分泌劑)。1 LUM-201 充當生長激素分泌受體的激動劑,刺激激激激素釋放並抑制生長抑素的釋放。2 已觀察 LUM-201 會增加人類內源性脈動激素分泌的幅度,模仿人類的自然模式生長激素分泌。3,4 該候選療法已在1,300多名成人和兒童患者中進行了研究,總體耐受性良好最常報告的不良事件是消化系統事件,包括食慾增加。還報告了肝酶的輕度升高,但沒有伴隨膽紅素的變化。LUM-201 已在美國和歐盟獲得孤兒藥稱號。
1 Patchett A.A. 等人L-163,191(MK-0677)的設計和生物活性:一種有效的口服活性生長激素促分泌劑,Proc Natl Acad Sci,1995,92:7001-7005。
2 霍華德 A.D. 等人垂體和下丘腦中一種在生長激素釋放中起作用的受體,《科學》,1996,273:974-977。
3 Nass R. 等人。口服生長激素模擬劑對健康老年人身體成分和臨床療效的影響,Ann Interner Med,2008,149:601-611。
4 Chapman I.M. 等人口服生長激素 (GH) 釋放肽模擬劑 MK-677 可刺激特定生長激素缺乏成人的生長激素/胰島素樣生長因子 I 軸,J Clin 內分泌學雜誌,1997,82 (10): 3455-3463。